Latest Articles
21 hours, 22 minutes ago
Clifford Chance Selects Autonomy Introspect
CAMBRIDGE, England and SAN FRANCISCO, Sept. 2 /PRNewswire/ -- Autonomy Corporation plc (LSE: AU. or AU.L), a global leader in infrastructure software for the enterprise, today announced that Clifford Chance ...
RedOrbit News - Technology - 1 a.m. Thursday 2nd September 2010 PDT
View Article
Related Articles
Email to Friend
1 day, 15 hours ago
Euro stocks boost drug sector
BOSTON (MarketWatch) -- Large-cap European drug makers were on a roll early Wednesday, feeding off the momentum of a positive trading session for the broader market in Europe. Top gainers ...
MarketWatch.com - MarketPulse - 6:55 a.m. Wednesday 1st September 2010 PDT
View Article
Related Articles
Email to Friend
Autonomy Positioned in Leaders Quadrant of the 2010 Web Content Management Magic Quadrant
CAMBRIDGE, England and SAN FRANCISCO, Sept. 1 /PRNewswire/ -- Autonomy Corporation plc (LSE: AU. or AU.L), a global leader in infrastructure software for the enterprise, today announced that it has ...
RedOrbit News - Technology - 1 a.m. Wednesday 1st September 2010 PDT
View Article
Related Articles
Email to Friend
2 days, 14 hours ago
Conway Reaches Settlement With GlaxoSmithKline for $3.75 Million
Bizjournals -- Kentucky Attorney General Jack Conways office has reached a $3.75 million settlement between the state and GlaxoSmithKline PLC over the alleged deceptive or false marketing of the drugmakers ...
BioSpace - 8 a.m. Tuesday 31st August 2010 PDT
View Article
Related Articles
Email to Friend
GlaxoSmithKline, Valeant Pharmaceuticals International Face US Delay for Epilepsy Drug, Receives New PDUFA Date
LONDON, RESEARCH TRIANGLE PARK, N.C., and ALISO VIEJO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK - News) and Valeant Pharmaceuticals International (NYSE:VRX - News) announced today the U.S. Food and ...
BioSpace - 7:20 a.m. Tuesday 31st August 2010 PDT
View Article
Related Articles
Email to Friend
Glaxo, Valeant face US delay for epilepsy drug
GlaxoSmithKline PLC and Valeant Pharmaceuticals International say they may have to wait an extra three months for the U.S. regulatory review of their potential epilepsy treatment ezogabine.
CNBC : All News, Video and Posts related to SECTOR: Health Care - 3:21 a.m. Tuesday 31st August 2010 PDT
View Article
Related Articles
Email to Friend
Glaxo, Valeant May Wait 3 More Months for Drug Review
GlaxoSmithKline Plc and Valeant Pharmaceuticals International may have to wait an extra three months for a review of their experimental epilepsy medicine after U.S. regulators sought more time to study ...
BusinessWeek.com -- Europe - 12:21 a.m. Tuesday 31st August 2010 PDT
View Article
Related Articles
Email to Friend
3 days ago
Glaxo, Valeant May Wait 3 More Months for Epilepsy Drug Review
GlaxoSmithKline Plc and Valeant Pharmaceuticals International may have to wait an extra three months for a review of their experimental epilepsy medicine after U.S. regulators sought more time to study ...
BusinessWeek.com -- Europe - 9:46 p.m. Monday 30th August 2010 PDT
View Article
Related Articles
Email to Friend
GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
LONDON, RESEARCH TRIANGLE PARK, N.C. and ALISO VIEJO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International (NYSE: VRX) announced today the U.S. Food and Drug Administration ...
RedOrbit - health - 5:15 p.m. Monday 30th August 2010 PDT
View Article
Related Articles
Email to Friend
Conway reaches settlement with GlaxoSmithKline
Kentucky Attorney General Jack Conway’s office has reached a $3.75 million settlement between the state and GlaxoSmithKline PLC over the alleged deceptive or false marketing of the drugmaker’s anti-nausea medications, ...
National Business News | bizjournals - 11:50 a.m. Monday 30th August 2010 PDT
View Article
Related Articles
Email to Friend
